PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Yvette Drew, Ruth Plummer
20091101
2009 Dec 1
Drug Resist Updat
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Drug Resist Updat. 2009 Dec;12(6):153-156, Yvette Drew, Ruth Plummer
The abundant nuclear enzyme poly(ADP-ribose)polymerase-1 (PARP-1) represents an important novel target in cancer therapy. PARP-1 is essential to the repair of single strand DNA breaks via the base excision repair pathway. Inhibitors of PARP-1 have been shown to enhance the cytotoxic effects of ionising radiation and DNA damaging chemotherapy agents such as the methylating agents and topoisomerase-I inhibitors. There are currently at least eight PARP inhibitors in clinical trial development. In vitro...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
